

22 August 2013

Shin Nippon Biomedical Laboratories, Ltd.

CEO and President, Ryoichi Nagata

Tokyo Stock Exchange, First Section: Code # 2395

Contact Information: CFO and Executive Vice President, Toshihiko Seki

(TEL: +81 (0)3 5565 5001)

Execution of Business Collaboration Agreement with BioView, Inc.

As of 22 August 2013, Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) announces the execution of a Business Collaboration Agreement with BioView, Inc. (Chiyoda-ku, Tokyo, President: Takashi Yokawa; hereafter “BioView”).

1. Basis for Business Collaboration

SNBL is contract provider of research services relating to the development of pharmaceuticals. These include the investigation of the effects and efficacy of pharmaceutical products on the central nervous system, for which there is a need for examinations using imaging techniques. High resolution MRI¹ has been attracting attention in recent years because of its non-invasive nature and of its capacity for not only morphological examination, but also functional examination. However high resolution MRI requires not only high-resolution MRI hardware, but also expertise in system construction, data analysis, and equipment and software maintenance. SNBL has an urgent need to obtain know-how and expertise in these techniques.

BioView specializes in imaging techniques for non-invasive examinations² for candidate drug research, basic biological research, and non-destructive investigations of plastics and large molecule compounds, focusing on high resolution MRI imaging at 4.7 Tesla, and possesses a wealth of experience and expertise in related imaging techniques.

Based on this background, SNBL and BioView have resolved to vigorously combine their joint expertise in their respective fields to offer clients a broad range of services.

¹ MRI (Magnetic Resonance Imaging) Magnetic resonance imaging (MRI) is a method that uses a magnetic resonance medical device with a magnetic field to take pictures lengthwise and crosswise inside the body, or the relevant apparatus. It features less of an adverse effect on the human body than the x-ray method.

² Non-invasive examination: A relatively safe examination for which insertion of a medical device into the skin or a body cavity is not necessary.

2 Contents of Business Collaboration

BioView will transfer the MRI system currently located at the BMA Laboratory in Kobe (Kobe Chuo-ku, Hyogo Prefecture) to SNBL's Drug Safety Laboratory (Miyanoura, Kagoshima-shi, Kagoshima Prefecture). This will enable both companies to offer clients efficient research in experimental animals, using high resolution MRI. Moreover, it will be possible to enter into contracts which have hitherto been difficult for the two companies to obtain when operating separately. In addition, the synergistic effect of enhancing external appeal can also be expected from the know-how and experience gained by SNBL through operating as a CRO for over a half century.

3. Overview of BioView (As of August 31, 2012)

(1) Name	Bioview Inc.	
(2) Address	2F Legend Iwamoto-cho, 2-16-16 Iwamoto-cho, Chiyoda-ku, Tokyo, Japan	
(3) Name and Title of Representative	Takashi Yokawa, PhD President and CEO	
(4) Business Description	Supports and performs contract studies such as basic biological and innovative drug research using MRI imaging	
(5) Capital	JPY20 000 000	
(6) Date Established	17 September, 2004	
(7) Major Shareholders and Ratio of Shares	Takashi Yokawa	64.00%
	Marc Van Cauteren	8.00%
	Hisao Inoue	2.00%
	Asami Masuda	2.00%
(8) Relationship Between the Parties		
Capital Ties	There is no capital relationship between the companies in the agreement. There are also no capital relations between the persons involved within two companies in the agreement.	
Human Relationship	There is no human relationship between the companies in the agreement. There are also no human relations between the persons involved within two companies in the agreement.	
Business Relationship	There is no business relationship between the companies in the agreement. There are also no business relations between the persons involved within two companies in the agreement.	
Statuses of Related Parties	BioView is not a related party of SNBL. Also, officials of BioView are not related parties of SNBL.	

(9)Consolidated Financial Condition and Results of the Company for Past 3 Years
Non-disclosure of information due to the collaboration party being an unlisted company.

4. Agreement Schedule

Execution Date of Business Collaboration Agreement	22 August, 2013
Start Date of Collaboration	September 2013 (Tentative) January 2014 Completion of move of BioView research to Kagoshima

5. Future Prospective

At the present time, the effect of this matter on the earnings of SNBL's current term is minimal.